Critical Pitfalls in the Flow Cytometric Analysis of Mast Cells in Patients With Systemic Mastocytosis
Cytometry Part A · 2025
DOI: 10.1002/cyto.a.24950 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytometry Part A, 2025. Verfasst von Abdulrazzaq Alheraky und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Mastocytosis, Systemic, Flow Cytometry, Mast Cells. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Systemic mastocytosis (SM) is a neoplastic disease characterized by abnormal mast cell (MC) activation and proliferation. Accurate diagnosis often relies on flow cytometry to detect aberrant CD25, CD2, and CD30 expression on MCs in bone marrow (BM). However, the frequently low abundance of MCs in BM, lack of completely specific antigens, and strong and highly variable autofluorescence can cause misinterpretation and lead to diagnostic misclassifications. We investigated the potentially interfering cell populations in flow cytometric analysis of MCs based on literature and expert insights, focusing on CD117, CD45, CD203c, and FcεR1. Additionally, we determined the most appropriate approach to quantify aberrant CD25, CD2, and CD30 expression. Apoptotic granulocytes frequently cause misinterpretation by mimicking strong CD117 and aberrant CD25, CD2, and CD30 expression, and must be distinguished from MCs with a viability dye like DRAQ7. CD117‐positive myeloblasts and promyelocytes overlap with CD117‐reduced immature MCs in advanced SM disease and can be differentiated using CD203c. Quantifying CD25, CD2, and CD30 expression is skewed on log‐transformed scales due to the strong and highly heterogeneous autofluorescence of MCs. Linear calculation of net expression levels of CD25, CD2, and CD30 yields the highest accuracies in predicting SM with a Youden index of 0.96, 0.93, and 0.88, respectively. Incorporating a viability dye like DRAQ7 and CD203c into the flow cytometric analysis for MC identification, along with the linear quantification of aberrant expression, significantly enhances the correct identification of MCs and increases the diagnostic accuracy of aberrant CD25, CD2, and CD30 expression for SM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Allergology, University of Groningen, Groningen, the Netherlands.
- Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
ORCID-Profile: Abdulrazzaq Alheraky
Zitieren
APA
Alheraky, A., Meijer, K., Nijk, M. T., Klein, S. K., Oude Elberink, H. N. G., Kema, I. P., & Mulder, A. B. (2025). Critical Pitfalls in the Flow Cytometric Analysis of Mast Cells in Patients With Systemic Mastocytosis. Cytometry Part A. https://doi.org/10.1002/cyto.a.24950
Vancouver
Alheraky A, Meijer K, Nijk MT, Klein SK, Oude Elberink HNG, Kema IP, et al. Critical Pitfalls in the Flow Cytometric Analysis of Mast Cells in Patients With Systemic Mastocytosis. Cytometry Part A. 2025. doi:10.1002/cyto.a.24950
BibTeX
@article{Alheraky2025,
author = {Alheraky, Abdulrazzaq and Meijer, Kees and Nijk, Marije T and Klein, Saskia K and Oude Elberink, Hanneke N G and Kema, Ido P and Mulder, André B},
title = {Critical Pitfalls in the Flow Cytometric Analysis of Mast Cells in Patients With Systemic Mastocytosis},
journal = {Cytometry Part A},
year = {2025},
doi = {10.1002/cyto.a.24950}
}
EUVIMED